1. Medtech Insight
  2. >>Geography
  3. >>North America
  4. >>United States

Companies See Opportunities In Expanding ENT Market

Competition breeds innovation, and the ear, nose, and throat (ENT) market, once a fairly quiet arena, is now positioned to host some spirited activity that should lead to new technologies. Several large device manufacturers have recently moved into the ENT space, and the sinus treatment segment of the market has become one of the focal points for emerging competitors, as companies work toward less-invasive treatment options.

Interest in the ear, nose, and throat (ENT) market has increased recently, and the arena now boasts several large device manufacturers that see possibilities in this space for innovative new minimally invasive products. Such competition is the ideal landscape for innovation, as the large companies battle for market share while start-up firms and venture capitalists see opportunities to take the market in new directions. Of course, a variety of conditions make up the ENT market, but therapies for sinus conditions, particularly chronic sinusitis, are developing into an early area of intense competition. The potential growth in this market is due not only to increased competition, but also to the sizeable patient base as well as reimbursement rates that are favorable for physicians right now.

The surgical ENT market, including the sinus surgery segment, has long been dominated by Medtronic PLC, which still holds the largest market share, and other major players in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

ConcertAI Launches Generative AI-Powered Precision Suite

 
• By Natasha Barrow

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 
• By Brian Bossetta

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

FDA Draft Guidance Introduces Electric Submission For Q-Sub Process

 
• By Brian Bossetta

The US FDA says its updated draft guidance represents one of several steps the agency is taking to develop electronic submission templates for the medical device industry. The document introduces stakeholders to currently available resources for supporting their pre-subs to the agency.

More from North America